NCT04970251View on ClinicalTrials.gov

Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Intraocular PressureNeovascular GlaucomaVascular Endothelial Growth Factor OverexpressionGlaucoma Secondary to Eye Inflammation
Interventions
DRUG

Aflibercept Ophthalmic

Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.

Trial Locations (1)

10700

Naris Kitnarong, Bangkoknoi

All Listed Sponsors
lead

Siriraj Hospital

OTHER

NCT04970251 - Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma | Biotech Hunter | Biotech Hunter